Document Detail

The boom that never was: results of a 10 year audit of paediatric growth hormone prescribing in Scotland.
MedLine Citation:
PMID:  12813777     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To investigate trends in paediatric growth hormone (GH) prescribing in Scotland. DESIGN: Annual audit of paediatric GH patients, analysed by geographical distribution, diagnosis, age and duration of treatment, dosage, sex ratio and prescribing body. SUBJECTS AND SETTING: Paediatric patients receiving GH who attended the four tertiary referral centres in Scotland: Glasgow, Edinburgh, Dundee and Aberdeen, from 1990-1999. RESULTS: The annual total number of paediatric GH recipients ranged from 296-393. The maximum was recorded in 1994, with a progressive decline thereafter. The latest total (296, 1999) represents a 19% decrease since 1990. There is a marked disparity between these figures and projections published by the Scottish Office Clinical Research and Audit Group (CRAG) in 1990 of 500 patients in 1995 and 600 by 2000. CRAG postulated that GH would prove efficacious in a wider range of conditions, that the number of survivors of childhood cancer would increase and that GH therapy would continue following clinical trials. While there has been a relative increase in oncology survivors during the 10-year period, the overall decline in numbers is largely attributable to familial short stature patients in whom there has been a five fold decrease, following completion of clinical trials of GH. The number of children classified "idiopathic growth hormone deficient" has also decreased, as the overlap between this condition and normal variant short stature is increasingly recognised. CONCLUSION: This expensive drug is being used relatively conservatively in Scotland, in the light of research experience. While a small degree of ad hoc usage is inevitable, we strongly support participation in national trials wherever possible. The adoption of an open approach with the Scottish Office regarding GH usage has proved beneficial in alleviating fear of escalating costs and preventing prescribing problems in a country in which 98% of GH is prescribed by general practitioners.
W F Paterson; M D Donaldson; S A Greene; C J Kelnar; P J Smail
Related Documents :
1563807 - Experience in the chemotherapy of severe, inoperable echinococcosis in man.
1243527 - Successful treatment of mastodynia with the prolactin inhibitor bromocryptine (cb 154).
1646217 - The endocrine effects of long-term treatment with mifepristone (ru 486).
16195777 - Outcome of surgery for acromegaly performed by different surgeons: importance of surgic...
18665107 - Aortic dissection and its endovascular management.
18251317 - Treating fallopian tube occlusion with a manual pelvic physical therapy.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Health bulletin     Volume:  58     ISSN:  0374-8014     ISO Abbreviation:  Health Bull (Edinb)     Publication Date:  2000 Nov 
Date Detail:
Created Date:  2003-06-19     Completed Date:  2003-07-11     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0012330     Medline TA:  Health Bull (Edinb)     Country:  Scotland    
Other Details:
Languages:  eng     Pagination:  457-66     Citation Subset:  IM    
Royal Hospital for Sick Children, Glasgow.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Child, Preschool
Drug Prescriptions
Drug Utilization Review*
Growth Hormone / administration & dosage,  therapeutic use*
Health Services Research
Medical Audit*
Pediatrics / standards
Physician's Practice Patterns*
Reg. No./Substance:
9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Neighbourhood cohesion and health in socially contrasting neighbourhoods: implications for the socia...
Next Document:  A review of otolaryngology equipment provision in a peripheral clinic setting.